Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.

We report the case of a patient with nephrotic syndrome and toxic epidermal necrolysis (TEN) caused by statin use. The associated hyperlipidemia was controlled using proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors. This is a unique case of treating hyperlipidemia with PCSK9 inhibitor in patient with nephrotic syndrome with TEN. A 54-year-old woman was admitted owing to generalized edema. She had massive proteinuria and was diagnosed with minimal change disease through kidney biopsy. Statins were used for treatment of hyperlipidemia associated with nephrotic syndrome; however, she developed a skin rash, which progressed to TEN. After discontinuation of statins, her skin symptoms improved; however, hyperlipidemia persisted. Because statins could not be administered, we injected evolocumab, a PCSK9 inhibitor, every 2 weeks. Since then, hyperlipidemia has been well controlled without any side effects. Thus, PCSK9 inhibitors may be a good alternative to control hyperlipidemia in patients with statin intolerance or serious side effects.